India's dual pricing pressures

Share this article:

India is struggling to keep its export drug business an enriching one. The Economic Times reports that international customers are aware of what the companies are charging in-country and now want similar prices for themselves. The Economic Times says companies are concerned that price parity would threaten their businesses, since India's price controls have driven prices down 60% for what the government considers essential medicines.

Share this article:
close

Next Article in Business Briefs

Email Newsletters

More in Business Briefs

Massachusetts painkiller ban overruled

A District Court says Massachusetts cannot ban opioid painkiller Zohydro.

Ranbaxy extends branded Diovan's life

Ranbaxy may be on the blocks, but it has a hold on the right to produce generics of the Novartis heart medication Diovan. Only problem: it can't, and that is good news for Novartis.

FDA approves Glaxo's GLP-1

Type-2 diabetes injection Tanzeum, also known as albiglutide, scored the approval Tuesday.